

[Click here to view linked References](#)

1 **Development and Biological Evaluation of Fluorophosphonate-Modified**

2 **Hydroxyapatite for Orthopaedic Applications**

3

4 **Gráinne Neary^{a*}, Ashley W. Blom^a, Anna I. Shiel^b, Gabrielle Wheway^b and Jason P. Mansell^{b*}**

5 ^a *Musculoskeletal Research Unit, University of Bristol, Level 1 Learning and Research Building BS10 5NB, UK.*

6 ^b *Department of Applied Sciences, University of the West of England, Frenchay Campus, Coldharbour Lane,*

7 *Bristol BS16 1QY, UK.*

8

9

10 **Corresponding author email addresses:*

11 grainne.neary6@gmail.com, jason.mansell@uwe.ac.uk

12

13

14

15

16

17

1 **1. Introduction**

2 Hydroxyapatite (HA) is a widely used biomaterial in orthopaedic implant technology as a bone graft substitute
3 [1, 2, 3, 4, 5] and as a coating for titanium implants [6, 7, 8, 9]. Traditional bone implant technologies have
4 focused on the mechanical properties of implants to optimise their performance [10]. However, it is now known
5 that the biological milieu has a significant impact on implant performance [11]. To this end, the use of
6 composite orthopaedic implant devices supplemented with bioactive agents is a prominent theme in biomaterials
7 research [12].

8 The term lysophosphatidic acid (LPA) is a moniker that refers to a diverse range of glycerophospholipids. The
9 LPAs are lipid growth factors involved in a wide variety of cell functions [13, 14] including proliferation [15,
10 16, 17], differentiation [18, 19] migration [20, 21], apoptosis and survival [22, 23]. Importantly the LPAs have
11 been shown to converge with active vitamin D3 metabolites to promote the maturation of osteoblast-like cells
12 [24, 25]. These features of LPA, its small size and ability to co-operate with D3 make it an especially desirable
13 molecule for implant functionalization.

14 LPAs sit within a class of compounds known as phosphonic acids (PA). Bisphosphonate drugs, which are used
15 to reduce bone resorption in conditions such as malignancy and calcification disorders, are also members of the
16 PA family. The ability of bisphosphonates to lock onto the mineral (HA) fraction of bone via their polar,
17 phosphor head groups is widely recognised [26]. This ability to avidly bind HA was exploited by Torres and co-
18 workers [27] who used an inert alkane PA, octadecylphosphonic acid (ODPA), for the subsequent addition of
19 silver to create an antibacterial HA finish.

20 In this study, we explored the use of (3S)1-fluoro-3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP), a
21 phosphatase-resistant LPA analogue, as a bioactive surface coating for HA. The effect of the FHBP coating on
22 MG63 cell maturation and proliferation was assessed. Survivorship of the coating after autoclaving, storage,
23 mechanical cleaning and reuse of the implant was determined. To our knowledge this is the first report of the
24 use of a bioactive LPA analogue as a surface coating for HA for orthopaedic implant use.

1 **2. Materials and Methods**

2 **2.1. Tissue Culture**

3 Human osteoblast-like cells (MG63, ECACC, item code: 86051601) were cultured in conventional tissue culture
4 flasks (750mL, Greiner, Frickenhausen, Germany) in a humidified atmosphere at 37°C and 5% CO₂. Cells were
5 grown to confluence in Dulbecco's modified Eagle medium (DMEM)/F12 nutrient mix (Gibco, Paisley,
6 Scotland) supplemented with sodium pyruvate (1mM final concentration), L-glutamine (4mM), streptomycin
7 (100 ng/mL), penicillin (0.1 units/mL) and 10% v/v foetal calf serum (Gibco, Paisley, Scotland). The growth
8 media was also supplemented with 1% v/v of a 100X stock of non-essential amino acids. For experimental
9 purposes MG63 cells were seeded and maintained in the same growth medium but devoid of both serum and
10 phenol red (SFCM).

11 **2.2. Biomaterial optimisation**

12 ***2.2.1. Determining the optimal FHBP concentration***

13 HA disks (Solid Hydroxyapatite Discs, item code: HAD60, Hitemco Medical, USA) were autoclaved (121°C
14 for 30 minutes) prior to use. Two different sizes of disks were used over the course of the study; small disks
15 with a surface area of 195.49mm² and large disks with a surface area of 304.02mm². Results are expressed per
16 mm² to account for this difference in disk sizes. FHBP (LPA analogue, item code: L-9118-0.5mg, Tebu-bio
17 Ltd., UK) was reconstituted to 500µM using 1:1 ethanol: cell culture-grade water and stored at -20°C. To
18 ascertain the optimal FHBP steeping concentration to functionalise the HA specimens, sample disks were placed
19 into 24-well tissue culture plates and exposed to varying concentrations of FHBP (0.25µM - 5µM) for a period
20 of 24 hours. Cell culture-grade water was used as the diluent. Unmodified, control HA disks were immersed in
21 cell culture-grade water.

22 Disks were removed from the wells after 24 hours and they were rinsed three times in cell culture-grade water
23 before being left to air dry within the tissue culture hood. Once dry they were then transferred to a clean 24-well
24 plate and seeded with MG63 cells. The optimal FHBP steeping concentration identified was used for all
25 subsequent experiments. This test was performed in duplicate with n=4 per time point for each test.

26 ***2.2.2. Determining the optimal steeping time***

27 Autoclaved HA disks were transferred to a fresh 24-well plate. 1ml of 2µM FHBP solution was added per well
28 and disks were steeped for a specified time period (15 minutes, 1 hour, 2 hours, 4 hours or 24 hours) in the

1 solution. Control disks were steeped in the vehicle for the specified time period. Disks were removed from the
2 wells after steeping and they were rinsed 3 times in cell culture-grade water before being left to air dry. Once
3 dry they were transferred to a clean 24-well plate and seeded with MG63 cells. The optimal steeping time
4 identified was used for all subsequent experiments. This experiment was performed in triplicate with n=4 per
5 time point for each test.

6 **2.3. Comparing cell maturation on FHBP-modified and control disks**

7 HA disks were steeped in a 2 μ M solution of FHBP for 3 hours. Control disks were steeped in vehicle only.
8 Modified and control disks were then rinsed 3 times in cell culture-grade water and left to air dry. Once dry the
9 disks were transferred to a fresh 24-well plate and seeded with MG63 cells. This test was performed a total of 12
10 times with n=2-4 per group for each test.

11 **2.4. Coating survivorship**

12 ***2.4.1. Autoclave survivorship***

13 HA disks were steeped in a 2 μ M solution of FHBP for 3 hours. One half of the batch of modified disks (n=3)
14 was autoclaved at standard clinical settings (121⁰C for 30 minutes) while the remaining half was not (n=3).
15 Unmodified autoclaved disks served as a negative control. The disks were transferred to a clean 24-well plate
16 and seeded with MG63 cells. This test was performed in triplicate with n=3-4 per group for each test.

17 ***2.4.2. Storage survivorship***

18 HA disks were steeped in a 2 μ M solution of FHBP for 3 hours. Control disks were steeped in the vehicle only.
19 Disks were either seeded with MG63 cells within 24 hours of modification or stored in air for a variable time
20 period (6 week or 6 months) before being seeded with cells. Tests were performed in duplicate with n=6 per
21 group for each time point for each test.

22 ***2.4.3. Mechanical cleaning and reuse***

23 HA disks were steeped in 2 μ M FHBP solution for 3 hours. Control disks were steeped in the vehicle. The disks
24 were seeded with MG63 cells and incubated under conventional issue culture conditions for 72 hours. After this
25 initial use, the disks were mechanically cleaned with an electrical toothbrush (ProclinicalTM C250, Colgate)
26 whilst being held under running tap water for 10 seconds. They were then re-autoclaved (121⁰C for 30 minutes)
27 prior to a second use. This test was performed 4 times with n=3 per group for each test.

1 **2.5. Biomaterial tissue culture model**

2 For each of the above experiments disks were seeded with 1ml of a 150,000 cells/ml suspension of MG63 cells
3 in SFCM spiked with calcitriol (D3) to a final concentration of 100nM [100nM, Calcitriol (10µg) (item code:
4 D1530-10UG, Sigma)]. Plates were incubated under conventional tissue culture conditions for 72 hours before
5 the alkaline phosphatase (ALP) activity of adherent cells was assessed.

6 **2.6. Alkaline Phosphatase assay to compare cell maturation on FHBP-modified and control HA disks**

7 After a 72 hour incubation period the medium in each well of a 24-well plate was removed. To ensure that the
8 ALP activity was only associated with cells attached to HA and not to the surrounding plastic, the sample HA
9 disks were transferred to a clean 24-well plate before being processed. An ALP substrate buffer was prepared
10 according to Delory and King [28]. Briefly, 0.1M sodium carbonate and 0.1M sodium bicarbonate solutions
11 were blended 7:3 to achieve a pH of 10.3. The resultant solution was supplemented with MgCl₂ to a final
12 concentration of 1mM from a 1M stock solution. A lysis solution was prepared from this buffer by performing a
13 10-fold dilution using cell culture-grade water followed by spiking with Triton X-100 to a final concentration of
14 0.1% v/v. The monolayers on the surface of the HA disks were lysed with 0.1ml of this solution. After 2
15 minutes, each disk was treated with 0.2ml of 15mM p-nitrophenylphosphate (p-NPP, di-Tris salt, Sigma, UK)
16 prepared in the ALP buffer. Lysates were left under conventional cell culturing conditions for 1 hour. After the
17 incubation period, 0.1ml aliquots were transferred to a 96-well micro titre plates and the absorbance read at 405
18 nm. An ascending series of p- nitrophenol (p-NP) (50-500µM) prepared in the substrate buffer enabled
19 quantification of product formation.

20 **2.7. MTS/PMS assay to compare cell proliferation on FHBP-modified and control HA disks**

21 HA disks were steeped in a 2µM solution of FHBP for 3 hours. Control disks were steeped in vehicle only.
22 Disks were seeded with 1ml of a 150,000 cells/ml suspension of MG63 cells in SFCM spiked with D3 to a final
23 concentration of 100nM. Plates were incubated under conventional tissue culture conditions for 72 hours, after
24 which the medium from each well was removed and the HA disks were transferred to a fresh 24-well plate
25 containing 0.5ml of SFCM per well. Cell number was determined using a combination of the tetrazolium
26 compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
27 salt (MTS, Promega, UK) and the electron-coupling reagent phenazine methosulphate (PMS). Each compound
28 was prepared separately in pre-warmed (37 °C) SFCM, allowed to dissolve, and then combined so that 1 ml of a
29 1 mg/ml solution of PMS was combined to 19 ml of a 2 mg/ml solution of MTS. A stock suspension of MG63

1 cells (1 X 10⁶ cells/ml) was serially diluted in SFM to give a series of known cell concentrations down to 25 X
2 10³ cells/ml to generate a standard curve. Each 0.5ml sample in the 24-well plate (HA disks) or in
3 microcentrifuge tubes (standard curve samples) was spiked with 0.1 ml of the MTS/PMS reagent mixture and
4 left for 45 min within a tissue culture cabinet. Once incubated, the medium surrounding the disks in the 24-well
5 plate was harvested and 0.1ml of each sample was dispensed onto a 96-well microtitre plate and the absorbances
6 read at 492 nm using a multiplate reader. Plotting the absorbances against known cell number, as assessed
7 initially using haemocytometry, enabled extrapolation of cell numbers for the experiments described herein.

8 **2.8. ALP gene expression analysis in MG63 cells**

9 **2.8.1. RNA purification**

10 MG63 cells were grown to 80% confluency in T75 flasks and subsequently serum starved for 24 hours. 24 hours
11 later, cells were treated with either media alone (control), D3 (100nM), FHBP (250nM) or vitamin FHBP/D3 in
12 combination. After 24 hours of treatment, total RNA was extracted from cells using TRI reagent (Sigma
13 Aldrich). RNA samples were treated with a TURBO DNA-free™ Kit (Ambion Inc.) using conditions
14 recommended by the manufacturers, and then cleaned with an RNA Clean & Concentrator™-5 spin column
15 (Zymo Research Corp). RNA was tested for quality and yield using a NanoDrop 1000 spectrophotometer and an
16 Agilent 2100 Bioanalyzer. Three independent biological replicates were prepared (n = 12).

17 **2.8.2. Library preparation**

18 Twelve total RNA samples were supplied and prepared into sequencing libraries of ~500ng by Bristol Genomics
19 Facility using the Illumina TruSeq Stranded mRNA kit. Briefly, RNA was polyA-selected, chemically
20 fragmented to approximately 200 nt in size (4 minute fragmentation time), and cDNA synthesized using random
21 hexamer primers. Each individual library received a unique Illumina barcode and pooled.

22 **2.8.3. RNA sequencing**

23 RNA-seq was performed on an Illumina NextSeq500 instrument with 12 libraries multiplexed and run across 4
24 lanes per flow-cell using 75 bp single end reads in high output mode. This resulted in more than 400 Million
25 reads per flow cell, with an average of 38 million reads per sample.

26 **2.8.4. RNA sequence analysis**

1 Raw reads from 4 lanes per sample (4 FASTQ files) were aligned to the human (*Homo sapiens*) full genome
2 (GRCh38/hg38) using STAR, a splice-aware aligner [29], with GRCh38.92.gtf gene model for splice junctions.
3
4 3 Again, using GRCh38.92.gtf, raw gene counts were estimated on merged BAM files using HTSeq, using the
5 union method and `-stranded=reverse` options [30]. Differential gene expression was analysed using DESeq2
6
7 4
8 5 [31] and normalised read counts were obtained.

6 **2.9. Statistical Analysis**

7 Results are expressed as mean \pm standard deviation (SD). Statistical analyses were performed using GraphPad
8 Prism 7.00 software. Unless otherwise stated all data was subjected to a one-way analysis of variance (ANOVA)
9 to test for statistical significance. A post hoc Tukey's multiple comparisons test was performed between all
10 groups where a P-value of <0.05 was detected. An unpaired t-test (2-tailed) was used to compare means of
11 modified and unmodified disks, and of freshly used and stored modified disks. P-values of <0.05 were
12 considered significant.

13

3. Results

3.1. Biomaterial Optimisation

3.1.1. Optimal FHBP concentration

There was a significant increase in cellular ALP expression for all modified groups steeped in concentrations of $\geq 0.5\mu\text{M}$ FHBP solution compared to the unmodified control. There was no significant difference in ALP expression between the 0.5, 1, 2 and $5\mu\text{M}$ FHBP treatment groups. Therefore an “optimal” concentration of $2\mu\text{M}$ FHBP was empirically selected from this concentration range (**Fig1**).

3.1.2. Optimal FHBP steeping time

ALP expression was significantly greater for all FHBP-modified disks compared to control disks irrespective of steeping time. ALP expression was not significantly different following steeping for 2, 6 or 24-hour time periods. Therefore an “optimal” steeping time of 3 hours was empirically chosen from this range (**Fig2**).

The optimal conditions identified ($2\mu\text{M}$ FHBP for 3 hours) were used for all subsequent experiments.

3.2. Comparing cell maturation on FHBP-modified and control disks

Cellular ALP activity was significantly greater for FHBP-modified disks (mean [p-NP] (μM) = 52.83 ± 34.71) compared to control disks (mean [p-NP] (μM) = 17.42 ± 5.934). This difference was significant ($p < 0.0001$) (**Fig3**).

3.3. Comparing cell proliferation on FHBP-modified and control disks

Cellular proliferation was significantly greater on FHBP-modified disks (mean cell number $\times 1000 = 110.97 \pm 38.8$) compared to control disks (mean cell number = 76.3 ± 35.92). This difference was significant ($p = 0.0087$) (**Fig4**).

3.4. Autoclave survival

ALP expression did not significantly differ between the FHBP-modified autoclaved and non-autoclaved groups (mean [p-NP] (μM) = 58.83 ± 30.78 and 60.75 ± 27.98 respectively, $p = 0.9813$). The mean ALP activity of modified groups (autoclaved and non-autoclaved) was significantly greater than that of the control group ($p = 0.0024$ and 0.0015 respectively) (**Fig5**).

1 **3.5. Storage survival**

2 The mean ALP activity of the modified stored groups was greater than that of the control groups after storage
3 for 6 weeks and 6 months. This difference was significant at both time points ($p < 0.001$). This information is
4 summarised in **Table 1**.

5 **3.6. Mechanical Cleaning and Reuse**

6 There was a 67% decline in cellular ALP activity for reused FHBP-modified disks compared to single use
7 FHBP-modified disks (mean [p-NP] (μM) = 26.84 ± 11.74 and 81.56 ± 49.28 respectively). This difference was
8 significant ($p = < 0.0001$). ALP activity did not significantly differ between the reused FHBP-modified group and
9 the control (single use and reused) groups ($p = 0.9947$ and 0.8438 respectively) (**Fig6**).

10 **3.7. ALP gene expression analysis**

11 MG63 cells were treated in culture with either media alone (control), D3, FHBP, or a combination of FHBP and
12 D3. Treatment with the FHBP/D3 combination resulted in a significant increase in normalised ALP gene
13 expression compared to all other treatments ($p \leq 0.0001$), and, notably, a 7-fold increase in ALP expression
14 compared to treatment with FHBP alone (**Fig7**).

4. Discussion

Autogenous bone grafts remain the gold standard in bone defect repair [32, 33]. However, there are issues associated with autogenous graft use, including donor site morbidity, limited tissue availability and prolonged operative time [34, 35]. Synthetic bone substitutes are being increasingly used in the clinical setting [32], providing an impetus to develop bone substitutes that satisfy the criteria of an “ideal bone graft”.

Synthetic HA is a widely used bone substitute. It is a non-toxic compound with a similar chemical composition to human bone mineral [36, 37]. It is traditionally regarded as an osteoconductive material [35], providing a mechanical framework to support bone repair.

We have shown that coating HA with FHBP enhanced the maturation of MG63 cells in the presence of D3, thereby improving its osteoinductive properties. In agreement with this, MG63 cells that were co-treated with FHBP and D3 in tissue culture flasks showed elevated ALP gene expression. The MG63 cell line is an osteosarcoma-derived, transformed human cell line that exhibits features of the immature osteoblast, including trivial basal ALP expression. Maturation towards a mature osteoblast phenotype is associated with increased expression of ALP, an event that is synonymous with bone tissue formation [38, 39]. In the context of orthopaedic implants this is expected to improve osseointegration. Since our discovery that LPA and D3 co-operate to synergistically enhance osteoblast ALP expression we consistently find that the marked increase in this enzyme consequent to LPA/FHBP co-stimulation is not a result of raised cell number [40, 41] and therefore in keeping with a pro-differentiating function of this steroid hormone. We compared cell number between FHBP-modified and control HA disks. Although we observed an increase in cell number on FHBP-treated disks compared to control disks, this increase was modest (1.5x) compared to the increased ALP activity observed (3x). This suggests that the increased ALP activity observed was not simply a consequence of increased cell proliferation but also a consequence of accelerated cell maturation. This is further supported by our ALP gene expression data which provides compelling evidence for an increase in ALP gene expression for FHBP/D3 co-treated MG63 cells, an effect that has not been paralleled by an increase in cell number in our previous works [40, 41].

There are several reasons why we used an LPA analogue as a surface coating for HA. Firstly, LPA, in combination with D3, synergistically enhances human osteoblast maturation [24, 25]. LPA analogues are amenable to large scale production. Their natural affinity for HA simplifies manufacturing, and, because of their small size and lysophospholipid properties, they are robust molecules resistant to the rigours of implant handling

1 and sterilisation. Finally, antimicrobial properties of LPA family members have previously been reported [42,
2 43]. Although not investigated as part of this study, it has previously been shown that surface modification of
3 titanium with an LPA analogue (16: 0 MPPA) deterred the attachment of methicillin-resistant *Staphylococcus*
4 *aureus* to the implant surface [38]. Identifying strategies to prevent implant infection is a prominent theme in
5 biomaterials research and has important public health implications in terms of reducing the reliance of modern
6 medicine on antimicrobials.

7 In order to be considered for clinical applications, an implant coating must be safe, stable, resistant to
8 sterilisation, amenable to reuse and resilient to mechanical forces. We have shown persistent bioactivity of the
9 FHBP coating following ambient storage for 6 months. The coating survived autoclaving at standard clinical
10 settings, and the coating process was performed as a single-step procedure under physiological conditions,
11 thereby eliminating biocompatibility and cytotoxicity concerns. These features are expected to improve the
12 translational prospects of this technology.

13 There was a significant loss of FHBP bioactivity following mechanical cleaning and reuse, which represents a
14 limitation of its utility as an implant coating. Although implants are generally intended for single clinical use,
15 there are a variety of circumstances in which they may need to be reused. Cleaning and sterilisation are key
16 steps in reconditioning the implant to its initial state for reuse [44]. The reason for the loss of bioactivity is
17 unclear and it contrasts with the findings of Mansell *et al.* [45] for their work on FHBP- and LPA-modified
18 titanium. A possible explanation for this discrepancy relates to differences in the material properties and
19 physical robustness of titanium and HA.

20 Failure to demonstrate successful adhesion and proliferation of MG63 cells on the modified HA disks represents
21 a potential limitation of this work. However, HA is widely recognised as a biocompatible substance, hence its
22 widespread use as a bone graft substitute and as a coating for metallic prostheses [46]. Indeed, in a previous
23 work by us we have depicted osteoblasts firmly attached on the surface of HA disks together with evidence of
24 proliferation in response to an LPA analogue [47].

25 Surface characterisation using techniques such as x-ray spectroscopy, scanning electron microscopy and/or
26 atomic force microscopy, are commonly used to validate the presence of coatings on biomedical implants.
27 However, we elected to focus on the identification of a biologically active surface, which we consider to be a
28 more suitable test for a product that is ultimately intended for clinical applications.

1 This work represents a logical progression from the work of Torres et al. [27] who exploited the natural affinity
2 of members of the phosphonic acids for HA by using ODPAs as linker molecules to attach silver ions. To our
3 knowledge ours is the first report of the use of a phosphonic acid as a biomimetic coating for HA. Evaluating the
4 antimicrobial potential of the coating and improving its resilience to mechanical stress and reuse are important
5 next steps in the translational process.

6

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **5. Conclusions**

2 To our knowledge this is the first report of successful functionalization of a HA construct intended for
3 orthopaedic applications with FHBP to improve the biological properties of the implant. This was achieved in a
4 facile and scalable manner. Accelerated maturation of osteoblasts is predicted to secure superior integration of
5 the implant with host bone, thereby minimising implant micro motion. Further work is required to improve the
6 survivorship of the coating to mechanical cleaning and reuse.

7

1 References

- 2 [1] Bucholz RW, Carlton A, Holmes RE. Hydroxyapatite and tricalcium phosphate bone graft substitutes.
3 Orthop Clin North Am. 1987;18(2):323-4.
- 4 [2] Blom A, Wylde V, Livesey C, Whitehouse MR, Eastaugh-Waring S, Bannister GC, Learmonth ID.
5 Impaction bone grafting of the acetabulum at hip revision using a mix of bone chips and a biphasic porous
6 ceramic bone graft substitute. Acta Orthop. 2009;80(2):150-4.
- 7 [3] Shibuya K, Kurosawa H, Takeuchi H, Niwa S. The medium-term results of treatment with hydroxyapatite
8 implants. J Biomed Mater Res B Appl Biomater. 2005;75(2):405-13.
- 9 [4] Whitehouse MR, Dacombe PJ, Webb JCJ, Blom AW. Impaction grafting of the acetabulum with ceramic
10 bone graft substitute mixed with femoral head allograft: high survivorship in 43 patients with a median follow-
11 up of 7 years: a follow-up report. Acta Orthop. 2013;84(4):365-70.
- 12 [5] Whitehouse MR, Dacombe PJ, Webb JCJ, Blom AW. Impaction grafting of the acetabulum with ceramic
13 bone graft substitute: high survivorship in 43 patients with a mean follow-up period of 4 years. Acta Orthop.
14 2013;84(4):371-6.
- 15 [6] Cook SD, Thomas KA, Kay JF, Jarcho M. Hydroxyapatite-coated titanium for orthopaedic implant
16 applications. Clin Orthop Relat Res. 1988;232:225-43.
- 17 [7] Geesink RGT, de Groot K, Klein CPAT. Bonding of bone to apatite-coated implants. J Bone Joint Surg Br.
18 1988;70(10):17-22.
- 19 [8] Downey CF, Twomey B, O'Neill L, Stanton KT. Co-blasting of titanium surfaces with an abrasive and
20 hydroxyapatite to produce bioactive coatings: substrate and coating characterisation. J Biomater Appl.
21 2014;28(5): 767-78.
- 22 [9] Murakami A, Arimoto T, Suzuki D, Iwai-Yoshida M, Otsuka F, Shibata Y, Igarashi T, Kamijo R, Miyazaki
23 T. Antimicrobial and osteogenic properties of a hydrophilic-modified nanoscale hydroxyapatite coating on
24 titanium. Nanomedicine. 2012;8(3): 374-82.
- 25 [10] Blom AW, Cunningham JL, Hughes G, Lawes TJ, Smith N, Blunn G, Learmonth ID, Goodship AE. The
26 compatibility of ceramic bone graft substitutes as allograft extenders for use in impaction grafting of the femur.
27 J Bone Joint Surg Br. 2005;87(3):421-5.
- 28 [11] Goodman SB, Yao Z, Keeney M, Yang F. The Future of Biologic Coatings for Orthopaedic Implants.
29 Biomaterials. 2013;34(13):3174-83.
- 30 [12] Billström GH, Blom AW, Larsson S, Beswick AD. Application of scaffolds for bone regeneration
31 strategies: current trends and future directions. Injury. 2013;44(Suppl. 1):28-33.
- 32 [13] Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer.
33 2003;3:582-91.
- 34 [14] Choi JW, Herr DR, Noguch K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN,
35 Chun J. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50: 157-86.
- 36 [15] Leve F, Peres-Moreira RJ, Binato R, Abdelhay E, Morgado-Díaz JA. LPA Induces Colon Cancer Cell
37 Proliferation through a Cooperation between the ROCK and STAT-3 Pathways. PLoS One.
38 2015;10(9):e0139094.
- 39 [16] Yamada T, Yano S, Ogino H, Ikuta K, Kakiuchi S, Hanibuchi M, Kanematsu T, Taniguchi T, Sekido Y,
40 Sone S. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells
41 through lysophosphatidic acid receptors, LPA1 and LPA2. Cancer Res. 2008;99(8) :1603-10.
- 42 [17] van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH. Lysophosphatidate-Induced Cell
43 Proliferation: Identification and Dissection of Signalling Pathways Mediated by G Proteins. Cell. 1989;59:45-
44 54.

- 1 [18] Evseenko D, Latour B, Richardson W, Corselli M, Sahaghian A, Cardinal S, Zhu Y, Chan R, Dunn B,
2 Crooks GM. Lysophosphatidic Acid Mediates Myeloid Differentiation within the Human Bone Marrow
3 Microenvironment. *PLoS One*. 2013;8(5): e63718.
- 4 [19] Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh DS, Yoon MS, Chang CL, Jung JS, Kim JH.
5 Cancer-Derived Lysophosphatidic Acid Stimulates Differentiation of Human Mesenchymal Stem Cells to
6 Myofibroblast-Like Cells. *Stem cells*. 2008;26(3):789-97.
- 7 [20] Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H.
8 Lysophosphatidic Acid and Autotaxin Stimulate Cell Motility of Neoplastic and Non-neoplastic Cells through
9 LPA1. *J Biol Chem*. 2004;279:17634-39.
- 10 [21] Stähle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, Hall A, Gierschikand P, Giehl K.
11 Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. *J Cell Sci*.
12 2003;116:3835-46.
- 13 [22] Ye X, Ishii I, Kingsbury MA, Chun J. Lysophosphatidic acid as a novel cell survival/apoptotic factor.
14 *Biochim Biophys Acta-Mol Cell Biol L*. 2002;1585(2-3):108-13.
- 15 [23] Weiner JA, Chun J. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid.
16 *Proc Natl Acad Sci U.S.A*. 1999;96(9):5233-8.
- 17 [24] Gidley J, Openshaw S, Pring ET, Sale S, Mansell JP. Lysophosphatidic acid cooperates with
18 $1\alpha,25(\text{OH})_2\text{D}_3$ in stimulating human MG63 osteoblast maturation. *Prostaglandins Other Lipid Mediat*.
19 2006;80(1-2):46-61.
- 20 [25] Mansell JP, Farrar D, Jones S, Nowghani M. Cytoskeletal reorganisation, $1\alpha,25$ -dihydroxy vitamin D3 and
21 human MG63 osteoblast maturation. *Mol Cell Endocrinol*. 2009;305(1-2):38-46.
- 22 [26] Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy
23 MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH. Bisphosphonates:
24 an update on mechanisms of action and how these relate to clinical efficacy. *Ann NY Acad Sci*. 1007;1117:209-
25 57.
- 26 [27] Torres N, Oh S, Appleford M, Dean DD, Jorgensen JH, Ong JL, Agrawal CM, Mani G. Stability of
27 antibacterial self-assembled monolayers on hydroxyapatite. *Acta Biomater*.2010; 6(8):3242-55.
- 28 [28] Delory GE, Kind EJ. A Sodium Carbonate-Bicarbonate buffer for Alkaline Phosphatases. *Biochem J*.
29 1945;37.
- 30 [29] Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras T. STAR:
31 ultrafast universal RNA-seq aligner. *Bioinformatics*;29(1):15-21.
- 32 [30] Anders S, Theodor Pyl P, Huber W. HTSeq- a Python framework with high-throughput sequencing data.
33 *Bioinformatics*. 2015;31(2):166-9.
- 34 [31] Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with
35 DESeq2. *Genome Biol*. 2014;15:550.
- 36 [32] Campana C, Milano G, Pagano E, Barba M, Cicione C, Salonna G, Lattanzi W, Logroscino G. Bone
37 substitutes in orthopaedic surgery: from basic science to clinical practice. *J Mater Sci Mater Med*.
38 2014;25(1):2445-61.
- 39 [33] Miron RJ, Zhang YFD. Osteoinduction: A Review of Old Concepts and New Standards. *J Dent Res*.
40 2012;91(8):736-44.
- 41 [34] Blokhuis T, Calori GM, Schmidmaier G. Autograft versus BMPs for the treatment of non-unions: What is
42 the evidence? *Injury*. 2013;44(S1):S40-4.
- 43 [35] Sen MK, Miclau T. Autologous iliac crest bone graft: Should it still be the gold standard for treating
44 nonunions? *Injury, Int J Care Injured*. 2007;38(S1):S75-80.

- 1 [36] Shankar R, Singh D, Shaikh S, Singh G, Yadav A, Jain R. Bone Regeneration in Osseous Defects Using
 2 Hydroxyapatite Graft and the Extent of Ossification in Osseous Defects Treated Without Grafts: A Comparative
 3 Evaluation. *J Maxillofac Oral Surg.* 2011;10:123-6.
- 4 [37] Silva CC, Valente MA, Graca MPF, Sombra ASB. The modulus formalism used in the dielectric analysis
 5 of hydroxyapatite and calcium phosphate with titanium formed by dry ball milling. *J Non Cryst Solids.*
 6 2005;351(33-36):2945-50.
- 7 [38] Skindersoe ME, Krogfelt KA, Blom A, Zhang J, Jiang G, Prestwich GD, Mansell JP. Dual Action of
 8 Lysophosphatidate-Functionalised Titanium: Interactions with Human (MG63) Osteoblasts and Methicillin
 9 Resistant *Staphylococcus aureus*. *PLoS One.* 2015;10(11):e0143509.
- 10 [39] Golub EE, Boesze-Battaglia K. The role of alkaline phosphatase in mineralization. *Curr Opin Orthop.*
 11 2007;18:444-8.
- 12 [40] Lancaster S, Blackburn J, Blom A, Makishima M, Ishizawa M, Mansell J. 24,25-Dihydroxyvitamin D3
 13 cooperates with a stable fluoromethylene LPA receptor agonist to secure human (MG63) osteoblast maturation.
 14 *Steroids*;83: 53-61.
- 15 [41] Mansell JP, Barbour M, Moore C, Nowghani M, Pabbruwe M, Sjoström T, Blom AW. The synergistic
 16 effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and
 17 hydroxyapatite surface. *Biomaterials.* 2010; 31(2): 199-206.
- 18 [42] Laux DC, Corson JM, Givskov M, Hentzer A, Moller A, Wosencroft KA, Olsen JC, Krogfelt KA,
 19 Goldberg JB, Cohen PS. Lysophosphatidic acid inhibition of the accumulation of *Pseudomonas aeruginosa*
 20 PAO1 alginate, pyoverdinin, elastase and LasA. *Microbiology.* 2002;148:1709-23.
- 21 [43] Krogfelt KA, Utley M, Krivan HC, Laux DC, Cohen PS. Specific phospholipids enhance the activity of
 22 β -lactam antibiotics against *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 2000;46(3):377-84.
- 23 [44] Park JH, Olivares-Navarrete R, Baier RE, Meyer AE, Tannenbaum R, Boyan BD, Schwartz Z. Effect of
 24 cleaning and sterilization on titanium implant surface properties and cellular response. *Acta Biomater.*
 25 2002;8(5):1966-75.
- 26 [45] Mansell JP, Brown J, Knapp JG, Faul CF, Blom AW. Lysophosphatidic Acid-Functionalised Titanium as a
 27 superior surface for supporting human osteoblast (MG63) maturation. *Eur Cell Mater.* 2012;23:348-61.
- 28 [46] Hench LL, Polak JM. Third-Generation Biomedical Materials. *Science.* 2002; 295: 1014-17.
- 29 [47] Mansell JP, Barbour M, Moore C, Nowghani M, Pabbruwe M, Sjoström T, Blom AW. The synergistic
 30 effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and
 31 hydroxyapatite surfaces. *Biomaterials.* 2010; 31 (2): 199-206.

33 Acknowledgements

34 This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the
 35 Wellcome Trust Institutional Strategic Support Fund. The funding body had no role in study design; in the
 36 collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the
 37 article for publication.

38 This work was also funded by the National Institute of Health Research (i4i Programme, Fluorophosphonate
 39 biofunctionalisation of biomaterials for orthopaedic applications – II-LA-0315-20004). Professor Blom is also

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust
2 and the University of Bristol.

3 The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the
4 National Institute for Health Research or the Department of Health.

5 Special thanks to the Functional Neurosurgery research group at the University of Bristol for their valuable
6 input.

7 **Conflict of Interest**

8 The authors declare that they have no conflict of interest.

9
10
11

Determining the optimal FHBP Concentration (n=2)




Fig1

The optimal concentration of FHBP solution to coat HA disks for enhanced MG63 maturation lies between 0.5-5µM. There was a significant increase in ALP expression for all treated groups compared to the control vehicle group at concentrations of $\geq 0.5\mu\text{M}$ FHBP. There was no significant difference in ALP expression between the 0.5, 1, 2 or 5 μM FHBP groups. The data depicted represent the mean and standard deviation of 4 replicates and are representative of 2 pooled experiments. Significant differences are depicted by asterisks (**** $P \leq 0.0001$, *** $P \leq 0.001$, ** $P \leq 0.01$, ns $P > 0.05$)

Determining the optimal FHBP steeping time (n=3)




Fig2

The optimal steeping time in FHBP solution for enhanced maturation of MG63 cells on modified HA disks lies between 2-24 hours. ALP expression was significantly greater by MG63 cells adherent to FHBP-modified disks compared to unmodified disks at all time points investigated. There was no significant difference in ALP expression between the 2, 6 or 24-hour groups. The data depicted represent the mean and standard deviation of 3 (n=1) or 4 (n=2) replicates and are representative of 3 pooled experiments. Significant findings are depicted by asterisks (**** $P \leq 0.0001$, *** $P \leq 0.001$, ** $P \leq 0.01$, * $P \leq 0.05$, ns $P > 0.05$)




Fig3

Modification of HA disks with a surface coating of FHBP accelerates the maturation of adherent MG63 cells. This figure shows that the ALP activity of MG63 cells adherent to the surface of a HA disk that had been modified by a surface coating of 2µM FHBP was greater than that of MG63 cells adherent to the surface of an unmodified HA disk. The data depicted represent the mean and standard deviation of a minimum of 2 replicates and are representative of 12 pooled experiments. Significant differences are depicted by asterisks (**** $P \leq 0.0001$).




Fig4

Modification of HA disks with a surface coating of FHBP promotes cell proliferation. This figure shows that surface modification of HA disks results in an increased number of adherent MG63 cells. However the increase in cell number is modest compared to the increased cell maturation that is observed when MG63 cells are grown on FHBP-modified HA disks (see Fig3). The data depicted represent the mean and standard deviation and are representative of 3 independent experiments with 6 replicates per group. The significant difference is depicted by an asterisk (** $P \leq 0.01$).

Survivorship of FHBP coating following Autoclaving (n=3)




Fig5

The FHBP coating can withstand autoclaving at standard clinical settings. There was no significant difference in ALP activity between MG63 cells adherent to autoclaved (AC) or non-autoclaved FHBP-modified disks. The data depicted represent the mean and standard deviation of a minimum of 3 replicates and are representative of 3 pooled experiments. Statistical significance is depicted by asterisks (** $P \leq 0.01$)

Survivorship following Mechanical Cleaning and Reuse (n=4)




Fig6

The bioactivity of the FHBP coating is lost following mechanical cleaning, irrigation and reuse. This figure shows that there was a significant decline in cellular ALP activity once the FHBP-modified HA disk had been mechanically cleaned and reused compared to single use FHBP- modified disks. The data depicted represent the mean and standard deviation of 3 replicates and are representative of 4 pooled experiments. Significant results are depicted by asterisks (**** $P \leq 0.0001$)





Fig7

Co-treatment of MG63 cells in tissue culture with FHBP and D3 results in a significant increase in ALP gene expression compared to treatment with D3, FHBP, or vehicle. Significant differences are depicted by asterisks (**** $P \leq 0.0001$, *** $P = 0.0001$).

Note: All figures shown have been created using GraphPad Prism 7.00 software.

Time	Vehicle [p-NP] (μM)	2 μM FHBP [p-NP] (μM)	P-Value (Test versus Control)
Baseline	75.81 \pm 22.14	121.52 \pm 25.92	0.0017*
6 weeks	69 \pm 12.97	165.67 \pm 50.47	<0.0001*
6 months	16.92 \pm 9.8	108.36 \pm 55.13	<0.0001*

Table 1: Summary of the osteoblast ALP activity at control and FHBP-modified HA surfaces – a six month ambient storage study. At the specified times Human (MG63) osteoblasts were seeded on to control and FHBP-functionalised HA discs at a density of 15×10^4 cells/ml/disc in the presence of 100nM D3. After a three day conventional culture the discs were processed for total ALP activity using p-nitrophenylphosphate as the substrate and quantification of p-nitrophenol (p-NP). An increase in p-NP for the FHBP-HA discs reflects a greater extent of osteoblast maturation at these surfaces compared to non-functionalised controls. This difference in mean ALP activity was significant at all time points investigated ($p < 0.05$). Significant differences are depicted by asterisks.



Depicted is a stylised summary of hydroxyapatite (HA) surface modification using an analogue of lysophosphatidic acid, FHBP. **A.** HA surfaces are simply steeped in an aqueous solution of 2 μ M FHBP. **B.** The polar head group of some FHBP molecules react with available hydroxyl residues at the mineral surfaces forming robust HA–O–P bonds leaving acyl chain extensions perpendicular to the HA surface. These fatty acyl chains provide points of integration for other FHBP molecules to facilitate their self-assembly. This final surface finish enhanced the human osteoblast maturation response to calcitriol, the active vitamin D3 metabolite.

[Click here to view linked References](#)

Abstract

1 There is an incentive to functionalise hydroxyapatite (HA) for orthopaedic implant use with bioactive agents to
2 encourage superior integration of the implants into host bone. One such agent is (3S) 1-fluoro-3-hydroxy-4-
3 (oleoyloxy) butyl- 1-phosphonate (FHBP), a phosphatase-resistant lysophosphatidic acid (LPA) analogue. We
4 investigated the effect of an FHBP-HA coating on the maturation of human (MG63) osteoblast-like cells.
5 Optimal coating conditions were identified and cell maturation on modified and unmodified, control HA
6 surfaces was assessed. Stress tests were performed to evaluate coating survivorship after exposure to mechanical
7 and thermal insults that are routinely encountered in the clinical environment. MG63 maturation was found to be
8 3 times greater on FHBP-modified HA compared to controls ($p < 0.0001$). There was no significant loss of
9 coating bioactivity after autoclaving ($P = 0.9813$) although functionality declined by 67% after mechanical
10 cleaning and reuse ($p < 0.0001$). The bioactivity of modified disks was significantly greater than that of controls
11 following storage for up to 6 months ($p < 0.001$). Herein we demonstrate that HA can be functionalised with
12 FHBP in a facile, scalable manner and that this novel surface has the capacity to enhance osteoblast maturation.
13 Improving the biological performance of HA in a bone regenerative setting could be realised through the simple
14 conjugation of bioactive LPA species in the future.
15

16
17 **Keywords:** Hydroxyapatite; Lysophosphatidic acid; Biomaterial functionalisation; Bone graft; vitamin D.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Change of authorship request form (pre-acceptance)

Please read the important information on page 4 before you begin

This form should be used by authors to request any change in authorship including changes in corresponding authors. Please fully complete all sections. Use black ink and block capitals and provide each author's full name with the given name first followed by the family name.

Please note: In author collaborations where there is formal agreement for representing the collaboration, it is sufficient for the representative or legal guarantor (usually the corresponding author) to complete and sign the Authorship Change Form on behalf of all authors.

Section 1: Please provide the current title of manuscript

(For journals: Please provide the manuscript ID, title and/or DOI if available.)

(For books: Please provide the title, ISBN and/or DOI if available.)

Manuscript ID no. in case of unpublished manuscript:

DOI in case of published manuscript:

ISBN (for books):

Title: Development and Biological Evaluation of Fluorophosphonate-Modified Hydroxyapatite for Orthopaedic Applications
--

Section 2: Please provide the previous authorship, in the order shown on the manuscript before the changes were introduced. Please indicate the corresponding author by adding (CA) behind the name.

	First name(s)	Family name	ORCID or SCOPUS id, if available
1 st author	Gráinne	Neary	
2 nd author	Ashley W.	Blom	
3 rd author	Anna I.	Shiel	
4 th author	Jason P.	Mansell	
5 th author			
6 th author			
7 th author			

Please use an additional sheet if there are more than 7 authors.

Change of authorship request form (pre-acceptance)

Section 3: Please provide a justification for change. Please use this section to explain your reasons for changing the authorship of your manuscript, e.g. what necessitated the change in authorship? Please refer to the (journal) policy pages for more information about authorship. Please explain why omitted authors were not originally included and/or why authors were removed on the submitted manuscript.

Gabrielle Wheway is being added to the author list because of her contribution to the revised version of this manuscript.

Section 4: Proposed new authorship. Please provide your new authorship list in the order you would like it to appear on the manuscript. Please indicate the corresponding author by adding (CA) behind the name. If the corresponding author has changed, please indicate the reason under section 3.

	First name(s)	Family name (this name will appear in full on the final publication and will be searchable in various abstract and indexing databases)
1 st author	Gráinne	Neary
2 nd author	Ashley W.	Blom
3 rd author	Anna I.	Shiel
4 th author	Gabrielle	Wheway
5 th author	Jason P.	Mansell
6 th author		
7 th author		

Please use an additional sheet if there are more than 7 authors.

Section 5: Author contribution, Acknowledgement and Disclosures. Please use this section to provide a new disclosure statement and, if appropriate, acknowledge any contributors who have been removed as authors and ensure you state what contribution any new authors made (if applicable per the journal or book (series) policy). **Please ensure these are updated in your manuscript - after approval of the change(s) - as our production department will not transfer the information in this form to your manuscript.**

New acknowledgements:

The Functional Neurosurgery research group and the NIHR are now acknowledged in the acknowledgements section because they were erroneously omitted from original versions of this manuscript.

New Disclosures (financial and non-financial interests, funding):

The authors have no new financial or non-financial disclosures to declare.

The NIHR is now recognised as a funding source for the work carried out in this manuscript.

New Author Contributions statement (if applicable per the journal policy):

Gabrielle Wheway performed the experimental work, data acquisition and data interpretation for the ALP gene expression aspects of this work. She also contributed to and reviewed the final manuscript.






State 'Not applicable' if there are no new authors.

rr

Change of authorship request form (pre-acceptance)

Section 6: Declaration of agreement. All authors, unchanged, new and removed *must* sign this declaration.

(NB: Please print the form, sign and return a scanned copy. Please note that signatures that have been inserted as an image file are acceptable as long as it is handwritten. Typed names in the signature box are unacceptable.) * Please delete as appropriate. Delete all of the bold if you were on the original authorship list and are remaining as an author.

	First name	Family name		Signature	Affiliated institute	Date
1 st author	Gráinne	Neary	I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.		University of Edinburgh-present University of Bristol- at time of work	17th June 2018
2 nd author	Ashley W.	Blom	I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.		University of Bristol	18th June 2018
3 rd author	Anna I.	Shiel	I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.		University of the West of England	18th June 2018
4 th authors	Gabrielle	Wheway	I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.		University of the West of England	18th June 2018
5 th author	Jason P.	Mansell	I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.		University of the West of England	18th June 2018
6 th author			I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.			
7 th author			I agree to the proposed new authorship shown in section 4 / and the addition/removal* of my name to the authorship list.			

Please use an additional sheet if there are more than 7 authors.

Important information. Please read.

- Please return this form, fully completed, to Springer Nature. We will consider the information you have provided to decide whether to approve the proposed change in authorship. We may choose to contact your institution for more information or undertake a further investigation, if appropriate, before making a final decision.
- By signing this declaration, all authors guarantee that the order of the authors are in accordance with their scientific contribution, if applicable as different conventions apply per discipline, and that only authors have been added who made a meaningful contribution to the work.
- Please note, we cannot investigate or mediate any authorship disputes. If you are unable to obtain agreement from all authors (including those who you wish to be removed) you must refer the matter to your institution(s) for investigation. Please inform us if you need to do this.
- If you are not able to return a fully completed form within **30 days** of the date that it was sent to the author requesting the change, we may have to withdraw your manuscript. We cannot publish manuscripts where authorship has not been agreed by all authors (including those who have been removed).
- Incomplete forms will be rejected.